Motilal Oswal Nifty MidSmall Healthcare Index Fund
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
Growthvine rating: 2/5 — ranked #170 of 245 in category.
Fund basics
| Category | Equity: Index |
|---|
| NAV | ₹12.20 (as of 2026-10-01) |
|---|
| AUM | ₹47 Cr |
|---|
| Expense ratio | 0.54% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Swapnil P Mayekar |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −17.54% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 67.6% |
|---|
| Small cap | 32.4% |
|---|
Concentration
| Top 5 holdings | 39.1% |
|---|
| Top 10 holdings | 60.0% |
|---|
| Total holdings | 30 |
|---|
Top holdings
- Laurus Labs Limited — 11.2%
- Lupin Ltd — 8.0%
- Aurobindo Pharma Ltd. — 7.2%
- Fortis Healthcare Ltd — 7.1%
- Glenmark Pharmaceuticals ltd — 5.6%
- Alkem Laboratories Limited — 4.7%
- Biocon Ltd. — 4.4%
- Ipca Laboratories Ltd. — 4.1%
- Mankind Pharma Limited — 4.1%
- Gland Pharma Limited — 3.5%
Top sectors
- Pharma & Biotech — 78.9%
- Healthcare — 21.5%
- Cash — −0.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 15.5% | — | — |
| 2025 | −1.5% | — | — |